TAK
$20.08+2.40%
as of close, Oct 20, 2026
☾ AH $20.08 +2.40%
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)Stock · Healthcare
TAK SEC filings (2026)
CIK 1395064 · Pharmaceutical Preparations (SIC 2834)
704 filings on EDGAR since 2007 · 8 annual, 0 quarterly, 343 current · financial statements · earnings
Latest 20-F
Jun 17, 2026
fiscal year to Mar 31, 2026
Latest 8-K
Sep 14, 2026
current report
Filings on file
704
since 2007, 193 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
September 2026
August 2026
- Aug 318-K8-K · Report of a foreign private issuer
- Aug 19Insider salePlump Andrew Stewart (President, R&D · Director) sold 19,651 ADS shares for $363K at $18.49 under a 10b5-1 plan
- Aug 18Insider saleGreenway Nicola Deidre Petal (Chief Human Resources Officer) sold 12,980 ADS shares for $235K at $18.11
- Aug 11Insider saleShannon Elaine Mary (Pres., Global Supply & Quality) sold 20,363 ADS shares for $357K at $17.55
- Aug 10Insider salePlump Andrew Stewart (President, R&D · Director) sold 165,393 ADS shares for $2.8M at $17.10
- Aug 10Insider saleKim Julie So-Young (President and CEO · Director) sold 89,090 ADS shares for $1.5M at $17.10
- Aug 10Insider saleBitetti Teresa Marie (President, OBU) sold 50,012 ADS shares for $855K at $17.10
- Aug 10Insider saleDuprey Lauren Rusckowski (Chief Transformation Officer) sold 47,586 ADS shares for $814K at $17.10
- Aug 10Insider saleGreenway Nicola Deidre Petal (Chief Human Resources Officer) sold 41,377 ADS shares for $722K at $17.10–$17.51
- Aug 10Insider salePlatford Giles Richard (President, IBU) sold 31,083 ADS shares for $532K at $17.10
- Aug 10Insider saleFurney Natalie Anne Marie (Global General Counsel) sold 30,868 ADS shares for $528K at $17.10
- Aug 10Insider saleRicci Gabriele (Chief Data & Tech. Officer) sold 25,088 ADS shares for $429K at $17.10
- Aug 10Insider salePignagnoli Agosti Marcello (Head, Strat. & Port. Dev) sold 22,957 ADS shares for $393K at $17.10
- Aug 10Insider salePacheco Rhonda Janice (President, U.S. Business Unit) sold 16,901 ADS shares for $289K at $17.10
- Aug 10Insider saleFarajallah Awny Samaan Botros (Chief Medical Officer) sold 14,006 ADS shares for $240K at $17.10
- Aug 10Insider saleIbrahim Ramy Riad Ahmed (President, PDT BU) sold 7,277 ADS shares for $124K at $17.10
- Aug 10Insider saleShannon Elaine Mary (Pres., Global Supply & Quality) sold 3,978 ADS shares for $68K at $17.10
- Aug 68-K8-K · Report of a foreign private issuer
July 2026
- Jul 308-K8-K · Report of a foreign private issuer
- Jul 98-K8-K · Report of a foreign private issuer
- Jul 88-K8-K · Report of a foreign private issuer
June 2026
- Jun 298-K8-K · Report of a foreign private issuer
- Jun 268-K8-K · Report of a foreign private issuer
- Jun 248-K8-K · Report of a foreign private issuer
- Jun 248-K8-K · Report of a foreign private issuer
- Jun 248-K8-K · Report of a foreign private issuer
- Jun 17ReportAnnual report (foreign private issuer), FY2026 — revenue $29.78B (−1% y/y), net income −$1.01B, EPS −$0.32
- Jun 98-K8-K · Report of a foreign private issuer
- Jun 58-K8-K · Report of a foreign private issuer
- Jun 58-K8-K · Report of a foreign private issuer
- Jun 18-K8-K · Report of a foreign private issuer
May 2026
- May 268-K8-K · Report of a foreign private issuer
- May 268-K8-K · Report of a foreign private issuer
- May 268-K8-K · Report of a foreign private issuer
- May 268-K8-K · Report of a foreign private issuer
- May 268-K8-K · Report of a foreign private issuer
- May 198-K8-K · Report of a foreign private issuer
- May 138-K8-K · Report of a foreign private issuer
- May 138-K8-K · Report of a foreign private issuer
March 2026
- Mar 308-K8-K · Report of a foreign private issuer
- Mar 268-K8-K · Report of a foreign private issuer
- Mar 258-K8-K · Report of a foreign private issuer
- Mar 28-K8-K · Report of a foreign private issuer
February 2026
- Feb 108-K8-K · Report of a foreign private issuer
January 2026
- Jan 298-K8-K · Report of a foreign private issuer
December 2025
- Dec 188-K8-K · Report of a foreign private issuer
- Dec 88-K8-K · Report of a foreign private issuer
November 2025
- Nov 288-K8-K · Report of a foreign private issuer
October 2025
- Oct 308-K8-K · Report of a foreign private issuer
- Oct 308-K8-K · Report of a foreign private issuer
- Oct 308-K8-K · Report of a foreign private issuer
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $13.1M in 18 sales and bought nothing on the open market; 55 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Sep 14, 2026Form 4 | Duprey Lauren RusckowskiChief Transformation OfficerSold · ADS · $640K · 34,535 sh |
| Sep 2, 2026Form 4 | Plump Andrew StewartPresident, R&D · DirectorSold · ADS · $2.1M · 116,191 sh · 10b5-1 |
| Aug 19, 2026Form 4 | Plump Andrew StewartPresident, R&D · DirectorSold · ADS · $363K · 19,651 sh · 10b5-1 |
| Aug 18, 2026Form 4 | Greenway Nicola Deidre PetalChief Human Resources OfficerSold · ADS · $235K · 12,980 sh |
| Aug 11, 2026Form 4 | Shannon Elaine MaryPres., Global Supply & QualitySold · ADS · $357K · 20,363 sh |
| Aug 10, 2026Form 4 | Plump Andrew StewartPresident, R&D · DirectorSold · ADS · $2.8M · 165,393 sh |
| Aug 10, 2026Form 4 | Kim Julie So-YoungPresident and CEO · DirectorSold · ADS · $1.5M · 89,090 sh |
| Aug 10, 2026Form 4 | Bitetti Teresa MariePresident, OBUSold · ADS · $855K · 50,012 sh |
| Aug 10, 2026Form 4 | Duprey Lauren RusckowskiChief Transformation OfficerSold · ADS · $814K · 47,586 sh |
| Aug 10, 2026Form 4 ×2 | Greenway Nicola Deidre PetalChief Human Resources OfficerSold · ADS · $722K · 41,377 sh |
| Aug 10, 2026Form 4 | Platford Giles RichardPresident, IBUSold · ADS · $532K · 31,083 sh |
| Aug 10, 2026Form 4 | Furney Natalie Anne MarieGlobal General CounselSold · ADS · $528K · 30,868 sh |
| Aug 10, 2026Form 4 | Ricci GabrieleChief Data & Tech. OfficerSold · ADS · $429K · 25,088 sh |
| Aug 10, 2026Form 4 | Pignagnoli Agosti MarcelloHead, Strat. & Port. DevSold · ADS · $393K · 22,957 sh |
| Aug 10, 2026Form 4 | Pacheco Rhonda JanicePresident, U.S. Business UnitSold · ADS · $289K · 16,901 sh |
| Aug 10, 2026Form 4 | Farajallah Awny Samaan BotrosChief Medical OfficerSold · ADS · $240K · 14,006 sh |
| Aug 10, 2026Form 4 | Ibrahim Ramy Riad AhmedPresident, PDT BUSold · ADS · $124K · 7,277 sh |
| Aug 10, 2026Form 4 | Shannon Elaine MaryPres., Global Supply & QualitySold · ADS · $68K · 3,978 sh |
Awards, exercises, withholding and plan purchases · 55 transactions
| Date | Insider |
|---|---|
| Jul 10, 2026Form 4 | Furuta MilanoChief Financial Officer · DirectorOther · $82.0M · 16,619 sh |
| Jul 10, 2026Form 4 | Tsusaka MikiDirectorOther · $10.6M · 2,152 sh |
| Jul 10, 2026Form 4 | Iijima MasamiDirectorOther · $10.6M · 2,152 sh |
| Jul 10, 2026Form 4 | Reed Kimberly A.DirectorOther · $5.7M · 1,152 sh |
| Jul 10, 2026Form 4 | MARAGANORE JOHNDirectorOther · $5.7M · 1,152 sh |
| Jul 10, 2026Form 4 | GILLIS STEVENDirectorOther · $5.7M · 1,152 sh |
| Jul 10, 2026Form 4 | Miyabashira AsukaPresident, Japan Pharma B.U.Other · $5.0M · 1,022 sh |
| Jul 1, 2026Form 4 | Plump Andrew StewartPresident, R&D · DirectorAward · ADS · $0 · 125,390 sh |
| Jul 1, 2026Form 4 | Kim Julie So-YoungPresident and CEO · DirectorAward · ADS · $0 · 50,434 sh |
| Jul 1, 2026Form 4 | Pacheco Rhonda JanicePresident, U.S. Business UnitAward · ADS · $0 · 50,156 sh |
| Jul 1, 2026Form 4 | Platford Giles RichardPresident, IBUAward · ADS · $0 · 49,558 sh |
| Jul 1, 2026Form 4 | Duprey Lauren RusckowskiChief Transformation OfficerAward · ADS · $0 · 45,140 sh |
| Jul 1, 2026Form 4 | Bitetti Teresa MariePresident, OBUAward · ADS · $0 · 43,886 sh |
| Jul 1, 2026Form 4 | Furney Natalie Anne MarieGlobal General CounselAward · ADS · $0 · 43,886 sh |
| Jul 1, 2026Form 4 | Ricci GabrieleChief Data & Tech. OfficerAward · ADS · $0 · 37,616 sh |
| Jul 1, 2026Form 4 | Shannon Elaine MaryPres., Global Supply & QualityAward · ADS · $0 · 30,094 sh |
| Jul 1, 2026Form 4 | Pignagnoli Agosti MarcelloHead, Strat. & Port. Dev.Award · ADS · $0 · 27,586 sh |
| Jul 1, 2026Form 4 | Ibrahim Ramy Riad AhmedPresident, PDT BUAward · ADS · $0 · 25,078 sh |
| Jul 1, 2026Form 4 | Kim Julie So-YoungPresident and CEO · DirectorAward · $0 · 23,225 sh |
| Jul 1, 2026Form 4 | Kim Julie So-YoungPresident and CEO · DirectorAward · $0 · 22,800 sh |
| Jul 1, 2026Form 4 | Greenway Nicola Deidre PetalChief Human Resources OfficerAward · ADS · $0 · 22,570 sh |
| Jul 1, 2026Form 4 | Smoter Jennifer MarieChief Comm. & Gov. OfficerAward · ADS · $0 · 18,808 sh |
| Jul 1, 2026Form 4 | Farajallah Awny Samaan BotrosChief Medical OfficerAward · ADS · $0 · 17,554 sh |
| Jul 1, 2026Form 4 | Furuta MilanoChief Financial Officer · DirectorAward · $0 · 12,864 sh |
| Jul 1, 2026Form 4 | Furuta MilanoChief Financial Officer · DirectorAward · $0 · 12,300 sh |
| Jul 1, 2026Form 4 | Stoffels PaulusDirectorAward · $0 · 3,800 sh |
| Jul 1, 2026Form 4 | BROUSSARD BRUCE DDirectorAward · ADS · $0 · 3,800 sh |
| Jul 1, 2026Form 4 | Reed Kimberly A.DirectorAward · $0 · 3,800 sh |
| Jul 1, 2026Form 4 | MARAGANORE JOHNDirectorAward · $0 · 3,800 sh |
| Jul 1, 2026Form 4 | GILLIS STEVENDirectorAward · $0 · 3,800 sh |
| Jul 1, 2026Form 4 | Miyabashira AsukaPresident, Japan Pharma B.U.Award · $0 · 1,994 sh |
| Jul 1, 2026Form 4 | Tsusaka MikiDirectorAward · $0 · 1,937 sh |
| Jul 1, 2026Form 4 | Kimura KoichiroDirectorAward · $0 · 1,937 sh |
| Jul 1, 2026Form 4 | Iijima MasamiDirectorAward · $0 · 1,937 sh |
| Jul 1, 2026Form 4 | Tsusaka MikiDirectorAward · $0 · 1,800 sh |
| Jul 1, 2026Form 4 | Kimura KoichiroDirectorAward · $0 · 1,800 sh |
| Jul 1, 2026Form 4 | Iijima MasamiDirectorAward · $0 · 1,800 sh |
| Jul 1, 2026Form 4 | Miyabashira AsukaPresident, Japan Pharma B.U.Award · $0 · 1,500 sh |
| Jul 1, 2026Form 4 | BROUSSARD BRUCE DDirectorAward · $0 · 1,319 sh |
| Jul 1, 2026Form 4 | Reed Kimberly A.DirectorAward · $0 · 1,319 sh |
| Jul 1, 2026Form 4 | MARAGANORE JOHNDirectorAward · $0 · 1,319 sh |
| Jul 1, 2026Form 4 | GILLIS STEVENDirectorAward · $0 · 1,319 sh |
| Jul 1, 2026Form 4 | Stoffels PaulusDirectorAward · $0 · 1,307 sh |
| Apr 27, 2026Form 4 | Plump Andrew StewartPresident, R&D · DirectorAward · ADS · $0 · 212,470 sh |
| Apr 27, 2026Form 4 | Weber Christophe PierrePresident and CEO · DirectorAward · ADS · $0 · 165,370 sh |
| Apr 27, 2026Form 4 | Kim Julie So-YoungCEO - ElectAward · ADS · $0 · 105,416 sh |
| Apr 27, 2026Form 4 | Weber Christophe PierrePresident and CEO · DirectorAward · $0 · 78,978 sh |
| Apr 27, 2026Form 4 | Weber Christophe PierrePresident and CEO · DirectorAward · $0 · 78,900 sh |
| Apr 27, 2026Form 4 | Platford Giles RichardPresident, IBUAward · ADS · $0 · 72,124 sh |
| Apr 27, 2026Form 4 | Bitetti Teresa MariePresident, OBUAward · ADS · $0 · 64,988 sh |
| Apr 27, 2026Form 4 | Duprey Lauren RusckowskiChief Transformation OfficerAward · ADS · $0 · 59,990 sh |
| Apr 27, 2026Form 4 | Ricci GabrieleChief Data & Tech. OfficerAward · ADS · $0 · 34,994 sh |
| Apr 27, 2026Form 4 | Pignagnoli Agosti MarcelloHead, Strat. & Port. Dev.Award · ADS · $0 · 27,740 sh |
| Apr 27, 2026Form 4 | Furuta MilanoChief Financial Officer · DirectorAward · $0 · 7,814 sh |
| Apr 27, 2026Form 4 | Furuta MilanoChief Financial Officer · DirectorAward · $0 · 7,800 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 30 filings
| Filed | What it is |
|---|---|
| Sep 14, 20266-K | Report of a foreign private issuer |
| Aug 31, 20266-K | Report of a foreign private issuer |
| Aug 6, 20266-K | Report of a foreign private issuer |
| Jul 30, 20266-K | Report of a foreign private issuer |
| Jul 9, 20266-K | Report of a foreign private issuer |
| Jul 8, 20266-K | Report of a foreign private issuer |
| Jun 29, 20266-K | Report of a foreign private issuer |
| Jun 26, 20266-K | Report of a foreign private issuer |
| Jun 24, 20266-K | Report of a foreign private issuer |
| Jun 24, 20266-K | Report of a foreign private issuer |
| Jun 24, 20266-K | Report of a foreign private issuer |
| Jun 17, 202620-F | Annual report (foreign private issuer), FY2026 — revenue $29.78B (−1% y/y), net income −$1.01B, EPS −$0.32 |
| Jun 9, 20266-K | Report of a foreign private issuer |
| Jun 5, 20266-K | Report of a foreign private issuer |
| Jun 5, 20266-K | Report of a foreign private issuer |
| Jun 1, 20266-K | Report of a foreign private issuer |
| May 26, 20266-K | Report of a foreign private issuer |
| May 26, 20266-K | Report of a foreign private issuer |
| May 26, 20266-K | Report of a foreign private issuer |
| May 26, 20266-K | Report of a foreign private issuer |
| May 26, 20266-K | Report of a foreign private issuer |
| May 19, 20266-K | Report of a foreign private issuer |
| May 13, 20266-K | Report of a foreign private issuer |
| May 13, 20266-K | Report of a foreign private issuer |
| Mar 30, 20266-K | Report of a foreign private issuer |
| Mar 26, 20266-K | Report of a foreign private issuer |
| Mar 25, 20266-K | Report of a foreign private issuer |
| Mar 2, 20266-K | Report of a foreign private issuer |
| Feb 10, 20266-K | Report of a foreign private issuer |
| Jan 29, 20266-K | Report of a foreign private issuer |
2025 · 45 filings
| Filed | What it is |
|---|---|
| Dec 18, 20256-K | Report of a foreign private issuer |
| Dec 8, 20256-K | Report of a foreign private issuer |
| Nov 28, 20256-K | Report of a foreign private issuer |
| Oct 30, 20256-K | Report of a foreign private issuer |
| Oct 30, 20256-K | Report of a foreign private issuer |
| Oct 30, 20256-K | Report of a foreign private issuer |
| Oct 1, 20256-K | Report of a foreign private issuer |
| Sep 25, 20256-K | Report of a foreign private issuer |
| Sep 8, 20256-K | Report of a foreign private issuer |
| Jul 31, 20256-K | Report of a foreign private issuer |
| Jul 30, 20256-K | Report of a foreign private issuer |
| Jul 14, 20256-K | Report of a foreign private issuer |
| Jul 9, 20256-K | Report of a foreign private issuer |
| Jul 8, 20256-K | Report of a foreign private issuer |
| Jul 2, 20256-K | Report of a foreign private issuer |
| Jul 1, 20256-K | Report of a foreign private issuer |
| Jun 30, 20256-K | Report of a foreign private issuer |
| Jun 25, 202520-F | Annual report (foreign private issuer), FY2025 — revenue $30.04B (+2% y/y), net income $709.2M, EPS $0.22 |
| Jun 25, 20256-K | Report of a foreign private issuer |
| Jun 25, 20256-K | Report of a foreign private issuer |
| Jun 12, 20256-K | Report of a foreign private issuer |
| Jun 10, 20256-K | Report of a foreign private issuer |
| Jun 6, 20256-K | Report of a foreign private issuer |
| Jun 2, 20256-K | Report of a foreign private issuer |
| Jun 2, 20256-K | Report of a foreign private issuer |
| May 28, 20256-K | Report of a foreign private issuer |
| May 28, 20256-K | Report of a foreign private issuer |
| May 28, 20256-K | Report of a foreign private issuer |
| May 28, 20256-K | Report of a foreign private issuer |
| May 14, 20256-K | Report of a foreign private issuer |
| May 8, 20256-K | Report of a foreign private issuer |
| May 8, 20256-K | Report of a foreign private issuer |
| Apr 22, 20256-K | Report of a foreign private issuer |
| Apr 14, 20256-K | Report of a foreign private issuer |
| Apr 1, 20256-K | Report of a foreign private issuer |
| Mar 26, 20256-K | Report of a foreign private issuer |
| Mar 13, 20256-K | Report of a foreign private issuer |
| Mar 3, 20256-K | Report of a foreign private issuer |
| Mar 3, 20256-K | Report of a foreign private issuer |
| Feb 13, 20256-K | Report of a foreign private issuer |
| Jan 30, 20256-K | Report of a foreign private issuer |
| Jan 30, 20256-K | Report of a foreign private issuer |
| Jan 30, 20256-K | Report of a foreign private issuer |
| Jan 30, 20256-K | Report of a foreign private issuer |
| Jan 30, 20256-K | Report of a foreign private issuer |
2024 · 41 filings
| Filed | What it is |
|---|---|
| Dec 18, 20246-K | Report of a foreign private issuer |
| Dec 13, 20246-K | Report of a foreign private issuer |
| Dec 2, 20246-K | Report of a foreign private issuer |
| Oct 31, 20246-K | Report of a foreign private issuer |
| Oct 31, 20246-K | Report of a foreign private issuer |
| Oct 31, 20246-K | Report of a foreign private issuer |
| Sep 26, 20246-K | Report of a foreign private issuer |
| Jul 31, 20246-K | Report of a foreign private issuer |
| Jul 10, 20246-K | Report of a foreign private issuer |
| Jul 9, 20246-K | Report of a foreign private issuer |
| Jul 5, 20246-K | Report of a foreign private issuer |
| Jul 2, 20246-K | Report of a foreign private issuer |
| Jul 1, 20246-K | Report of a foreign private issuer |
| Jun 26, 202420-F | Annual report (foreign private issuer), FY2024 — revenue $29.46B (−1% y/y), net income $996.4M, EPS $0.31 |
| Jun 26, 20246-K | Report of a foreign private issuer |
| Jun 26, 20246-K | Report of a foreign private issuer |
| Jun 17, 20246-K | Report of a foreign private issuer |
| Jun 11, 20246-K | Report of a foreign private issuer |
| Jun 10, 20246-K | Report of a foreign private issuer |
| Jun 7, 20246-K | Report of a foreign private issuer |
| Jun 7, 20246-K | Report of a foreign private issuer |
| Jun 3, 20246-K | Report of a foreign private issuer |
| Jun 3, 20246-K | Report of a foreign private issuer |
| May 29, 20246-K | Report of a foreign private issuer |
| May 29, 20246-K | Report of a foreign private issuer |
| May 29, 20246-K | Report of a foreign private issuer |
| May 29, 20246-K | Report of a foreign private issuer |
| May 21, 20246-K | Report of a foreign private issuer |
| May 9, 20246-K | Report of a foreign private issuer |
| May 9, 20246-K | Report of a foreign private issuer |
| May 9, 20246-K | Report of a foreign private issuer |
| May 9, 20246-K | Report of a foreign private issuer |
| May 9, 20246-K | Report of a foreign private issuer |
| Apr 19, 20246-K | Report of a foreign private issuer |
| Apr 15, 20246-K | Report of a foreign private issuer |
| Mar 27, 20246-K | Report of a foreign private issuer |
| Feb 9, 20246-K | Report of a foreign private issuer |
| Feb 2, 20246-K | Report of a foreign private issuer |
| Feb 1, 20246-K | Report of a foreign private issuer |
| Feb 1, 20246-K | Report of a foreign private issuer |
| Jan 16, 20246-K | Report of a foreign private issuer |
2023 · 40 filings — 39 × 6-K, 1 × 20-F
2022 · 45 filings — 44 × 6-K, 1 × 20-F
2021 · 60 filings — 59 × 6-K, 1 × 20-F
2020 · 50 filings — 49 × 6-K, 1 × 20-F
2019 · 40 filings — 39 × 6-K, 1 × 20-F
2008 · 1 filing — 1 × ARS
| Filed | What it is |
|---|---|
| Jun 16, 2008ARS | Annual report to shareholders |
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 104 filings — 52 × 4, 31 × 3, 19 × 144 and 2 other forms
| Filed | What it is |
|---|---|
| Sep 15, 20264 | Insider transaction (Form 4) |
| Sep 10, 2026144 | Notice of proposed sale (Form 144) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 2, 2026144 | Notice of proposed sale (Form 144) |
| Aug 21, 20264 | Insider transaction (Form 4) |
| Aug 19, 20264 | Insider transaction (Form 4) |
| Aug 19, 2026144 | Notice of proposed sale (Form 144) |
| Aug 14, 2026144 | Notice of proposed sale (Form 144) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 10, 2026144 | Notice of proposed sale (Form 144) |
| Aug 6, 2026144 | Notice of proposed sale (Form 144) |
The newest 25 of 104 shown; the full year is on EDGAR.
2025 · 33 filings — 15 × 144, 8 × 13F-HR, 2 × 4 and 8 other forms
| Filed | What it is |
|---|---|
| Dec 9, 20254 | Insider transaction (Form 4) |
| Dec 9, 2025SCHEDULE 13G/A | Other filings |
| Dec 9, 2025144 | Notice of proposed sale (Form 144) |
| Dec 5, 2025144 | Notice of proposed sale (Form 144) |
| Dec 4, 2025144 | Notice of proposed sale (Form 144) |
| Nov 13, 202513F-HR | Other filings |
| Sep 19, 20254 | Insider transaction (Form 4) |
| Sep 19, 2025SCHEDULE 13D/A | Other filings |
| Aug 21, 2025N-PX | Other filings |
| Aug 8, 202513F-HR | Other filings |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jul 9, 2025144 | Notice of proposed sale (Form 144) |
| Jun 27, 2025424B2 | Prospectus supplement |
| Jun 27, 2025FWP | Free writing prospectus |
| Jun 26, 2025424B5 | Prospectus supplement |
The newest 25 of 33 shown; the full year is on EDGAR.
2024 · 26 filings — 13 × 144, 3 × SC 13D/A, 3 × SC 13G/A and 7 other forms
| Filed | What it is |
|---|---|
| Aug 22, 2024144 | Notice of proposed sale (Form 144) |
| Jul 31, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Jul 10, 2024144 | Notice of proposed sale (Form 144) |
| Jul 10, 2024144 | Notice of proposed sale (Form 144) |
| Jul 10, 2024144 | Notice of proposed sale (Form 144) |
| Jul 10, 2024144 | Notice of proposed sale (Form 144) |
| Jul 10, 2024144 | Notice of proposed sale (Form 144) |
| Jul 10, 2024144 | Notice of proposed sale (Form 144) |
| Jul 10, 2024144 | Notice of proposed sale (Form 144) |
| Jul 10, 2024144 | Notice of proposed sale (Form 144) |
| Jul 10, 2024144 | Notice of proposed sale (Form 144) |
| Jul 10, 2024144 | Notice of proposed sale (Form 144) |
| Jul 10, 2024144 | Notice of proposed sale (Form 144) |
| Jul 10, 2024144 | Notice of proposed sale (Form 144) |
| Jun 28, 2024424B2 | Prospectus supplement |
| Jun 28, 2024FWP | Free writing prospectus |
| Jun 27, 2024424B5 | Prospectus supplement |
| Jun 26, 2024F-3ASR | Registration and prospectus |
| Apr 25, 2024SD | Specialized disclosure (conflict minerals) |
| Apr 10, 2024SC 13D/A | Active holder above 5% (Schedule 13D), amended |
| Apr 1, 2024SC 13D/A | Active holder above 5% (Schedule 13D), amended |
| Feb 6, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Feb 5, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Jan 25, 20244 | Insider transaction (Form 4) |
| Jan 25, 2024SC 13D/A | Active holder above 5% (Schedule 13D), amended |
The newest 25 of 26 shown; the full year is on EDGAR.
2023 · 19 filings — 11 × 144, 4 × SC 13G/A, 1 × 4 and 3 other forms
Counted, not listed; the year is on EDGAR.
2022 · 18 filings — 4 × 4, 4 × SC 13G/A, 2 × 3 and 6 other forms
Counted, not listed; the year is on EDGAR.
2021 · 43 filings — 25 × 4, 8 × SC 13G/A, 4 × SC 13D/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2020 · 21 filings — 4 × SC 13G/A, 3 × 4, 2 × 424B2 and 10 other forms
Counted, not listed; the year is on EDGAR.
2019 · 23 filings — 7 × SC 13G, 5 × 3, 2 × 4 and 8 other forms
Counted, not listed; the year is on EDGAR.
2018 · 37 filings — 9 × SC TO-T/A, 8 × SC TO-C, 4 × CORRESP and 13 other forms
Counted, not listed; the year is on EDGAR.
2017 · 12 filings — 5 × SC TO-T/A, 3 × SC TO-C, 2 × SC 13D and 2 other forms
Counted, not listed; the year is on EDGAR.
2013 · 1 filing — 1 × SC 13G
Counted, not listed; the year is on EDGAR.
2010 · 2 filings — 1 × EFFECT, 1 × F-6
Counted, not listed; the year is on EDGAR.
2008 · 6 filings — 3 × F-6EF, 3 × SUPPL
Counted, not listed; the year is on EDGAR.
2007 · 4 filings — 3 × SUPPL, 1 × 12G3-2B
Counted, not listed; the year is on EDGAR.
About this data#
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) has 704 filings on EDGAR going back to 2007: 8 annual reports, 0 quarterly reports and 343 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 20-F, was filed on Jun 17, 2026 for the fiscal year ended Mar 31, 2026. The most recent 8-K, on Sep 14, 2026, covered a material event. Over the last 13 months insiders sold $13.1M in 18 sales and bought nothing on the open market; 55 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock), read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read TAK's latest 10-K?
- TAK's latest annual report, a 20-F, was filed on Jun 17, 2026 for the fiscal year ended Mar 31, 2026. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did TAK last file an 8-K?
- On Sep 14, 2026 it filed a current report. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02.
- Are TAK insiders buying or selling?
- Over the last 13 months insiders sold $13.1M in 18 sales and bought nothing on the open market; 55 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Duprey Lauren Rusckowski (Chief Transformation Officer) sold 34,535 shares on Sep 14, 2026 for $640K. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has TAK made?
- 704 filings are on EDGAR under the registrant records that have been Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock), going back to 2007; 193 of them are insider ownership forms (Forms 3, 4, 5 and 144).